ライフサイエンスコーパス: alveolar proteinosis

1 eted and dysfunctional, resembling pulmonary alveolar proteinosis.

2 tic of atherosclerotic lesions and pulmonary alveolar proteinosis.

3 from six patients with idiopathic pulmonary alveolar proteinosis.

4 rupt surfactant clearance, causing pulmonary alveolar proteinosis.

5 bodies isolated from patients with pulmonary alveolar proteinosis.

6 contributor to the pathogenesis of pulmonary alveolar proteinosis.

7 omatous inflammation leading to fibrosis and alveolar proteinosis.

8 vital lung function that prevents pulmonary alveolar proteinosis.

9 with chronic inflammation, and two had focal alveolar proteinosis.

10 n 79% and ventilatory defects 63%, pulmonary alveolar proteinosis 18%, pulmonary arterial hypertensio

11 We studied 12 subjects with pulmonary alveolar proteinosis, 61 healthy control subjects, and 1

12 t a lung disorder similar to human pulmonary alveolar proteinosis, a rare disease with congenital, in

13 fluids from healthy donors and patients with alveolar proteinosis also binds to M.tb.

14 sufficient GM-CSF signaling caused pulmonary alveolar proteinosis and excessive IL-6 signaling promot

15 ions are impaired in patients with pulmonary alveolar proteinosis and that GM-CSF autoantibodies caus

16 e syndrome, cigarette smoking, and pulmonary alveolar proteinosis and the implications of obesity and

17 llomavirus infections, lymphedema, pulmonary alveolar proteinosis, and myelodysplasia.

18 plasia, cytogenetic abnormalities, pulmonary alveolar proteinosis, and myeloid leukemias.

19 atherosclerosis, type 2 diabetes, pulmonary alveolar proteinosis, and obesity, have a chronic inflam

20 Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disorder invo

21 antibodies against GM-CSF underlie pulmonary alveolar proteinosis; associated infections are less wel

22 ing growth failure, renal disease, pulmonary alveolar proteinosis, autoimmune disorders and osteoporo

23 uman GM-CSF and IL-3 and developed pulmonary alveolar proteinosis because of elimination of mouse GM-

24 are linked to the pathogenesis of congenital alveolar proteinosis (CAP).

25 polyendocrine syndrome type I and pulmonary alveolar proteinosis, detecting ACAA levels consistent w

26 ptible to respiratory infections and develop alveolar proteinosis due to defects in innate immune fun

27 actant and cell debris in airways (pulmonary alveolar proteinosis) due to impaired development of alv

28 ant human Prdx6 and SP-A isolated from human alveolar proteinosis fluid were studied.

29 Neutrophils from subjects with pulmonary alveolar proteinosis had normal ultrastructure and diffe

30 Hereditary pulmonary alveolar proteinosis (hPAP) caused by granulocyte-macrop

31 l disorder identical to hereditary pulmonary alveolar proteinosis (hPAP) in children with CSF2RA or C

32 -/- mice resulting in complete correction of alveolar proteinosis in bitransgenic GM-/-, SP-C-GM+ mic

33 functional and prevented the development of alveolar proteinosis in mice transplanted with GM-Csf-re

34 CSF) gene by homologous recombination caused alveolar proteinosis in mice.

35 monary chronic interstitial inflammation and alveolar proteinosis, inflammation of the glandular stom

36 Idiopathic pulmonary alveolar proteinosis is caused by autoantibodies against

37 Mice lacking beta c show a pulmonary alveolar proteinosis-like disease and reduced numbers of

38 Both human SP-A (isolated from normal and alveolar proteinosis lungs) and SP-D (recombinant protei

39 ecombinant protein and protein isolated from alveolar proteinosis lungs) bound the conidia.

40 bronchiolitis obliterans (n = 21), pulmonary alveolar proteinosis (n = 12), pulmonary fibrosis (n = 1

41 idosis (occupational burden, 30%); pulmonary alveolar proteinosis (occupational burden, 29%); tubercu

42 ty from infection in patients with pulmonary alveolar proteinosis occurs in association with high lev

43 e at risk for later development of pulmonary alveolar proteinosis or other opportunistic infections,

44 hils are impaired in patients with pulmonary alveolar proteinosis, owing to the presence of GM-CSF au

45 erved that it is elevated in human pulmonary alveolar proteinosis (PAP) and in the GM-CSF knockout mo

46 -) mice, respectively) resulted in pulmonary alveolar proteinosis (PAP) but no hematologic abnormalit

47 rize the frequency and features of pulmonary alveolar proteinosis (PAP) in patients with ADA deficien

48 Pulmonary alveolar proteinosis (PAP) is a devastating lung disease

49 Pulmonary alveolar proteinosis (PAP) is a rare disease characteriz

50 Autoimmune pulmonary alveolar proteinosis (PAP) is a rare disease characteriz

51 Pulmonary alveolar proteinosis (PAP) is a rare disease with freque

52 Pulmonary alveolar proteinosis (PAP) is a rare disorder in which s

53 Pulmonary alveolar proteinosis (PAP) is a rare lung disease charac

54 Pulmonary alveolar proteinosis (PAP) is a rare lung disorder in wh

55 Pulmonary alveolar proteinosis (PAP) is a rare lung syndrome cause

56 Pulmonary alveolar proteinosis (PAP) is a rare syndrome characteri

57 Primary pulmonary alveolar proteinosis (PAP) is a rare syndrome characteri

58 Pulmonary alveolar proteinosis (PAP) is a syndrome characterized b

59 Pulmonary alveolar proteinosis (PAP) is an idiopathic lung disease

60 Rationale: Pulmonary alveolar proteinosis (PAP) is characterized by filling o

61 ystemic lupus erythematosus (SLE), pulmonary alveolar proteinosis (PAP) or multiple sclerosis) and co

62 In patients with pulmonary alveolar proteinosis (PAP) syndrome, disruption of granu

63 utoantibodies are thought to cause pulmonary alveolar proteinosis (PAP), a rare syndrome characterize

64 d tomography is characteristic for pulmonary alveolar proteinosis (PAP), it is not specific and has n

65 rom five independent kindreds have pulmonary alveolar proteinosis (PAP), progressive polycystic lung

66 asis and how its disruption causes pulmonary alveolar proteinosis (PAP), we evaluated lipid compositi

67 lineage cells and severe secondary pulmonary alveolar proteinosis (PAP).

68 cal meningitis who later developed pulmonary alveolar proteinosis (PAP).

69 imicrobial function in patients with primary alveolar proteinosis (PAP).

70 ophages that partially rescued the pulmonary alveolar proteinosis syndrome.

71 heir mRNAs, distinguishing the disorder from alveolar proteinosis syndromes.

72 phil dysfunction characteristic of pulmonary alveolar proteinosis was reproduced in a dose-dependent

73 ce of Stat5 signaling in AMs, mice developed alveolar proteinosis with altered lipid homeostasis.

74 Five patients developed pulmonary alveolar proteinosis without mutations in the granulocyt